155 related articles for article (PubMed ID: 25382826)
1. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil.
Pak YA; Posada MM; Bacon J; Long A; Annes W; Witcher J; Mitchell M; Tirona RG; Hall SD; Hillgren KM
Pharm Res; 2023 Nov; 40(11):2499-2511. PubMed ID: 36635486
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.
Pak YA; Long AJ; Annes WF; Witcher JW; Knadler MP; Ayan-Oshodi MA; Mitchell MI; Leese P; Hillgren KM
Drug Metab Dispos; 2017 Feb; 45(2):137-144. PubMed ID: 27895114
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.
Moulton RD; Ruterbories KJ; Bedwell DW; Mohutsky MA
Drug Metab Dispos; 2015 May; 43(5):756-61. PubMed ID: 25755052
[TBL] [Abstract][Full Text] [Related]
5. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Lowe S; Dean R; Ackermann B; Jackson K; Natanegara F; Anderson S; Eckstein J; Yuen E; Ayan-Oshodi M; Ho M; McKinzie D; Perry K; Svensson K
Psychopharmacology (Berl); 2012 Feb; 219(4):959-70. PubMed ID: 21847569
[TBL] [Abstract][Full Text] [Related]
6. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mehta MA; Schmechtig A; Kotoula V; McColm J; Jackson K; Brittain C; Tauscher-Wisniewski S; Kinon BJ; Morrison PD; Pollak T; Mant T; Williams SCR; Schwarz AJ
Psychopharmacology (Berl); 2018 Jul; 235(7):1875-1886. PubMed ID: 29564482
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
10. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
Kinon BJ; Millen BA; Zhang L; McKinzie DL
Biol Psychiatry; 2015 Dec; 78(11):754-62. PubMed ID: 25890643
[TBL] [Abstract][Full Text] [Related]
11. Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.
Ayan-Oshodi M; Wondmagegnehu ET; Lowe SL; Kryzhanovskaya L; Walker DJ; Kinon BJ
J Clin Psychopharmacol; 2012 Jun; 32(3):408-11. PubMed ID: 22544017
[TBL] [Abstract][Full Text] [Related]
12. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.
Mezler M; Geneste H; Gault L; Marek GJ
Curr Opin Investig Drugs; 2010 Jul; 11(7):833-45. PubMed ID: 20571979
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity.
Perkins EJ; Abraham T
Drug Metab Dispos; 2007 Oct; 35(10):1903-9. PubMed ID: 17646281
[TBL] [Abstract][Full Text] [Related]
14. A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia.
Stauffer VL; Baygani SK; Kinon BJ; Krikke-Workel JO
J Clin Psychopharmacol; 2014 Oct; 34(5):552-8. PubMed ID: 25006819
[TBL] [Abstract][Full Text] [Related]
15. Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia.
Zhang W; Mitchell MI; Knadler MP; Long A; Witcher J; Walling D; Annes W; Ayan-Oshodi M
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):462-70. PubMed ID: 25881753
[TBL] [Abstract][Full Text] [Related]
16. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD
Nat Med; 2007 Sep; 13(9):1102-7. PubMed ID: 17767166
[TBL] [Abstract][Full Text] [Related]
17. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats.
Bangphumi K; Kittiviriyakul C; Towiwat P; Rojsitthisak P; Khemawoot P
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):777-785. PubMed ID: 26563392
[TBL] [Abstract][Full Text] [Related]
19. Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.
Lappin G
J Clin Pharmacol; 2016 Jan; 56(1):11-23. PubMed ID: 26073308
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Rorick-Kehn LM; Johnson BG; Knitowski KM; Salhoff CR; Witkin JM; Perry KW; Griffey KI; Tizzano JP; Monn JA; McKinzie DL; Schoepp DD
Psychopharmacology (Berl); 2007 Jul; 193(1):121-36. PubMed ID: 17384937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
